This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
The EVD-LabNet is strengthening capacity for early detection and surveillance of (re)emerging viral diseases in the EU/EEA countries and EU Candidate Countries.
The Emerging and Vector-borne Diseases (EVD) team of ECDC communicates, consults and cooperates with EVD-Net on surveillance, response, prevention, control and preparedness aspects of EVDs and vectors, with particular focus on country needs and country support possibilities.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.
This document provides practical guidance to EU/EEA Member States willing to implement a pilot study for the harmonised and coordinated targeted genomic surveillance of SARS-CoV-2 at selected international points of entry (PoE), to complement national and international genomic surveillance.
This guidance document includes an updated summary of diagnostic PCR and serology together with detailed information on isolation, culture, identification and epidemiological typing of B. pertussis to help users choose the best methods within the local technical and financial provisions.